Developmental and epileptic encephalopathy 44 due to compound heterozygous variants in the UBA5 gene: a case report
Acta Epileptologica volume 5, Article number: 27 (2023)
Developmental and epileptic encephalopathy (DEE) is a group of rare inherited disorders characterized by intellectual disability, delayed development, epileptic seizures, and other related symptoms. DEE44 is caused by mutations in the UBA5 gene, which encodes a ubiquitin-like protein involved in protein degradation and cell signaling. However, there is limited information on the genotype–phenotype correlation of DEE44, and its clinical features remain to be fully characterized.
We report a 12-month-old infant who presented with epileptic spastic seizures beginning at 4 months of age, accompanied by overall developmental delay, short stature, microcephaly, inability to hold his head upright, chasing vision, and high muscle tone in the extremities. Genetic findings showed compound heterozygous mutations of the UBA5 gene: NM_024818 c.562C > T(p.R188X) from the mother and NM_024818 c.214C > T(p.R72C) from the father.
This case report expands the clinical spectrum of DEE44 and highlights the importance of considering DEE44 in the differential diagnosis of developmental delay and epilepsy, even in the absence of classical symptoms suggestive of the condition. We hope that this case report will advance the understanding of DEE44 and improve the expertise of clinicians and early diagnose of this disease.
Developmental and epileptic encephalopathy (DEE) 44 is an autosomal recessive neurological disorder caused by mutations in the UBA5 gene. The disease onset usually occurs within weeks or months after birth, with a variety of clinical signs and symptoms. The most common clinical manifestations are spasmodic seizures, global developmental delay, and electroencephalogram (EEG) hyperarrhythmia, consistent with clinical diagnosis of West syndrome. Most patients have poor prognosis, and some die in childhood [1, 2].
A 12-month-old male patient had convulsions without obvious causes at age of < 1 month. He showed spasmodic-tonic seizures with specific symptoms including staring of both eyes to one side, holding hands in front of the chest, head tilting to the right, sometimes accompanied by raising up of upper and lower limbs, rapid shaking of limbs, and crying. During epileptic spasms (sometimes occur in clusters), the child held his hands in front of his chest, his head deflected to the right, with or without upper and lower limb elevation, and his limbs shaked rapidly.
The attacks occurred during both awake and sleeping periods, more commonly during the former. After admission, a detailed consultation, physical examination, and comprehensive laboratory examination were conducted for the patient.
The patient’s parents reported no previous history of special diseases, infection, surgical trauma, food or drug allergies, or blood transfusions. The child was delivered by his mother (G1P1) spontaneously at 39 weeks with a birth weight of 2.75 kg and a birth height of 49 cm. There was no history of asphyxia or rescue at birth. The parents were in good health. They reported no intermarriage in the child’s family history and that the family did not have any history of genetic diseases. However, we noticed that the child had clear growth and developmental retardation. At the age of 1 year, the child could not stand up, tended to stare with poor fixation, could not grasp objects, and occasionally laughed but could not make “babbling” sounds. Physical examination showed a height of 61 cm (- 3 SD), weight of 5.8 kg (- 3 SD), and head circumference of 38 cm. In addition, the child was unable to raise his head or turn over on his own; he had a high palatine arch, palmar crease on the right hand and congenital laryngeal cartilage softening, with increased muscle tension and limb muscle strength of grade. During a vision examination, the child was able to follow light and objects, was sensitive to light reflection, and demonstrated a soft neck without resistance. He didn't show any pathological signs. Other cardiopulmonary and abdominal examinations also showed no obvious abnormalities.
A series of comprehensive laboratory examinations was conducted, including routine blood tests, urine tests, stool tests, liver and kidney function tests, myocardial enzymes tests, electrolytes tests, urine tandem mass spectrometry, blood tandem mass spectrometry, as well as tests for ceruloplasmin levels, homocysteine levels, parathyroid hormone levels, and blood ammonia levels. The above examinations had normal results. We further performed brain magnetic resonance imaging (MRI) and video EEG. MRI showed thinning of the corpus callosum (Fig. 1a, b). while the cerebellomedullary cistern was relatively full.
Video EEG demonstrated the following findings: (1) EEG background: no dominant rhythms in the occipital region; (2) multifocal and generalized epileptiform discharges throughout the entire brain region (Fig. 2 ); highly disorganized activities during wake and sleep periods (Fig. 2), (3) occurrence of multiple spasm attacks, in addition to tonic–clonic seizures (Fig. 3), tonic seizures (Fig. 4), and epileptic spasms (sometimes occuring in clusters) (Fig. 5).
The onset of the disease occurred at a young age, presenting with evident epilepsy symptoms, together with obvious abnormalities from head MRI examination and video EEG. Therefore, we highly suspected that the disease was attributed to genetic mutations, and an exome sequencing analysis was performed for the entire family of the patient. With the duly obtained informed consent from the child’s parents, peripheral blood was collected from the child and his parents for the whole-exome genetic sequencing (Beijing MyGenostics). The results of Sanger sequencing revealed that the child carried the complex heterozygous mutation of UBA5 c.562C > T(p.R188X). This mutation was derived from his parents. His mother had a heterozygous mutation, NM_024818: exon6: c.562C > T(p.R188X), while his father had no variants (Fig. 6). Interestingly, his father had a heterozygous mutation, NM_024818: exon3: c.214C > T(p.R72C), while his mother had no variants (Fig. 7). The child was finally diagnosed as DEE44 caused by UBA5 gene mutation. Concurrent with genetic testing, proactive treatment strategies were implemented, including administration of adrenocorticotropic hormone (ACTH) and magnesium sulfate shock therapy. Regrettably, the therapeutic outcome proved to be unsatisfactory, as the child continued to experience several seizures daily.
The UBA5 gene is located at chromosome 3q22.1 (OMIM: 610552), encoding ubiquitin-like modifier activating enzyme 5 (UBA5). The UBA5 protein is a member of the E1-like ubiquitin activator family, which activates ubiquitin-folding modifier 1, a ubiquitin-like posttranslational modifier protein, by forming high-energy thioester bonds . Animal studies have highlighted the importance of UBA5 in erythrocyte development, indicating its involvement in the hematopoietic process . Moreover, UBA5 has been identified as an essential player in the development of the nervous system. Mutations in the UBA5 gene have been found to be responsible for a range of clinical symptoms, such as significant motor deficits, shortened lifespan, and neuromuscular junction defects [1, 2, 5].
Mutations in the UBA5 gene have been identified as the underlying cause of DEE44 and spinocerebellar ataxia with autosomal recessive 24 (SCAR24), both of which are inherited in an autosomal recessive manner [1, 2, 5]. At present, nearly 30 cases of DEE44 have been reported. Children with DEE resulting from UBA5 gene mutations exhibit a range of clinical symptoms. The primary symptoms include microcephaly, short stature, visual impairment, mental retardation, motor impairment, and seizures. Secondary symptoms may also manifest, including hereditary cerebellar ataxia, abnormal gait, limb ataxia, dysarthria, horizontal nystagmus, cataracts, and cerebellar atrophy, which may be accompanied by demyelinating peripheral neuropathy [1, 2, 5,6,7,8,9,10,11,12]. SCAR24 is relatively rare in clinical practice. As reported by Duan et al. in 2016, the main clinical manifestations of SCAR24 are gait and limb ataxia, dysarthria, nystagmus, and cataracts . Brain imaging may show the presence of cerebellar atrophy, suggesting its progressive nature .
The case reported here had severe seizures, delayed overall development, short stature, and microcephaly. EEG recording showed hypsarrhythmia consistent with typical DEE44 manifestations. The UBA5 gene in this patient contained two mutations, c.562C > T(p.R188X) derived from his mother and c.214C > T (p.R72C) from his father. According to the guideline of the American College of Medical Genetics and Genomics (ACMG), the c.562C > T(p.R188X) variant is determined to be a pathogenic mutation and there are several case reports of recessive inheritance at this site . The other mutation c.214C > T (p.R72C) remains unclear for its clinical significance according to ACMG guidelines, although there are reports of recessive genetic cases at this locus . Based on the clinical presentation and the identified genetic mutation, we ruled out the possibility of SCAR24 and finally arrived at the diagnosis of DEE44.
Regrettably, there is no specific treatment for DEE44 at present. We administered a combined ACTH and magnesium sulfate treatment as a shock therapy based on the symptoms, but did not observe satisfactory clinical efficacy, as the child continued to experience several seizures every day. Additionally, the child was also treated with several anti-seizure medications, including valproate, topiramate, perampanel, vigabatrin, and clobazam. Despite these interventions, the child died of type I respiratory failure at the age of 1 year and 4 months.
We report a case of developmental epileptic encephalopathy induced by a compound heterozygous variant of the UBA5 gene. This report extends the understanding of the phenotypic and genetic variations associated with this disorder, and offer insights and guidance for clinicians in the diagnosis and management of similar cases.
Availability of data and materials
The data presented in this study are available on request from the corresponding author.
The American College of Medical Genetics and Genomics
Developmental and epileptic encephalopathy
Magnetic resonance imaging
Spinocerebellar ataxia with autosomal recessive 24
Colin E, Daniel J, Ziegler A, Wakim J, Scrivo A, Haack TB, et al. Biallelic Variants in UBA5 Reveal that Disruption of the UFM1 Cascade Can Result in Early-Onset Encephalopathy. Am J Hum Genet. 2016;99:695–703.
Muona M, Ishimura R, Laari A, Ichimura Y, Linnankivi T, Keski-Filppula R, et al. Biallelic Variants in UBA5 Link Dysfunctional UFM1 Ubiquitin-like Modifier Pathway to Severe Infantile-Onset Encephalopathy. Am J Hum Genet. 2016;99:683–94.
Komatsu M, Chiba T, Tatsumi K, Iemura S-I, Tanida I, Okazaki N, et al. A novel protein-conjugating system for Ufm1, a ubiquitin-fold modifier. EMBO J. 2004;23:1977–86.
Tatsumi K, Yamamoto-Mukai H, Shimizu R, Waguri S, Sou Y-S, Sakamoto A, et al. The Ufm1-activating enzyme Uba5 is indispensable for erythroid differentiation in mice. Nat Commun. 2011;2:181.
Duan R, Shi Y, Yu L, Zhang G, Li J, Lin Y, et al. UBA5 Mutations Cause a New Form of Autosomal Recessive Cerebellar Ataxia. PLoS ONE. 2016;11: e0149039.
Daida A, Hamano SI, Ikemoto S, Matsuura R, Nakashima M, Matsumoto N, et al. Biallelic loss-of-function UBA5 mutations in a patient with intractable West syndrome and profound failure to thrive. Epileptic Disord. 2018;20:313–8.
Low KJ, Baptista J, Babiker M, Caswell R, King C, Ellard S, et al. Hemizygous UBA5 missense mutation unmasks recessive disorder in a patient with infantile-onset encephalopathy, acquired microcephaly, small cerebellum, movement disorder and severe neurodevelopmental delay. Eur J Med Genet. 2018;62:97–102.
Briere LC, Walker MA, High FA, Cooper C, Rogers CA, Callahan CJ, et al. A description of novel variants and review of phenotypic spectrum in UBA5-related early epileptic encephalopathy. Mol Case Stud. 2021;7: a005827.
Cabrera-Serrano M, Coote DJ, Azmanov D, Goullee H, Andersen E, McLean C, et al. A homozygous UBA5 pathogenic variant causes a fatal congenital neuropathy. J Med Genet. 2020;57:835–42.
Al-Saady ML, Kaiser CS, Wakasuqui F, Korenke GC, Waisfisz Q, Polstra A, et al. Homozygous UBA5 Variant Leads to Hypomyelination with Thalamic Involvement and Axonal Neuropathy. Neuropediatrics. 2021;52:489–94.
Mignon-Ravix C, Milh M, Kaiser CS, Daniel J, Riccardi F, Cacciagli P, et al. Abnormal function of the UBA5 protein in a case of early developmental and epileptic encephalopathy with suppression-burst. Hum Mutat. 2018;39:934–8.
Liu N, Liu XM. Case report of developmental epileptic encephalopathy caused by UBA5 gene mutation and literature review. Chin J Appl Clin Pediatr. 2022;37:130–4 (In Chinese).
We appreciate the staff who supported this study.
This work was supported by Natural Science Foundation of Hainan Province of China (821RC1133).
Ethics approval and consent to participate
The study was approved by the Ethics Committee of Hainan Women and Children’s Medical Center in 2023 and informed consent was obtained from the patients or their legal guardians before any study-related procedures were performed.
Consent for publication
The authors declare no conflicts of interests.
About this article
Cite this article
Zhang, S., Lin, S., Wang, W. et al. Developmental and epileptic encephalopathy 44 due to compound heterozygous variants in the UBA5 gene: a case report. Acta Epileptologica 5, 27 (2023). https://doi.org/10.1186/s42494-023-00139-y